Elotuzumab, Iberdomide, and Dexamethasone after Ide-cel for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma and have tried at least 4 prior treatments, including an immunomodulating drug, a proteasome inhibitor, and a CD38-targeting antibody.
- You have received ide-cel (a CAR T-cell therapy) within the last 90 days and achieved at least a partial response to it.
- You are 18 years old or older and able to care for yourself (ECOG score of 0-2).
- You have adequate blood counts (like neutrophils, platelets, and hemoglobin) and kidney and liver function.
- You have not taken iberdomide before and are not on certain medications that could interfere.
- You agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
This trial tests a new combination of drugs (elotuzumab, isatuximab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with high-risk multiple myeloma. The goal is to see if this combination is safe and effective before and after a stem cell transplant.
This study tests a new CAR-T cell therapy called Eque-cel for people with multiple myeloma that no longer responds to lenalidomide. It aims to see if this treatment can help control the disease after 1-2 prior therapies.
This early-stage study tests whether giving a drug called iberdomide before collecting cells for CAR-T therapy can make the cells healthier and more effective in treating multiple myeloma that has come back or hasn't responded to previous treatments.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.